Skip to main content
Clinical Trials/NCT04534907
NCT04534907Not yet recruitingNot Applicable

Effectiveness of the Immersive Virtual Reality (VR) Treatment With Cognitive Behaviour Therapy (CBT) for Obsessive-Compulsive Disorder (OCD) : A Randomized Controlled Study

Shanghai Mental Health Center1 site in 1 country30 target enrollmentStarted: December 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
30
Locations
1
Primary Endpoint
Change in Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score

Study Overview

Brief Summary

This study will evaluate the clinical effectiveness ofthe Immersive Virtual Reality alongside exprosure and response Prevention (ERP) Treatment in cognitive-Behavioral Therapy for Obsessive-compulsive Disorder, and the underlying neural mechanism by electroencephalography (EEG) and eye-tracking methodology .

Detailed Description

The current study aims to the clinical effectiveness of the Immersive Virtual Reality alongside exprosure and response Prevention (ERP) Treatment in cognitive-Behavioral Therapy for Obsessive-compulsive Disorder. 30 OCD patients whose symptom were mainly associated with "contamination/clean" , "Symmetry/precision", "Examination" and "Sex" will be randomized into two groups (i.e. VR ERP or ERP). The treatment will be performed twice a week for the first two weeks. And for the next 4 week, the treatment for OCD patients will be undertook once a week. There will be 8 times in total. The investigators will assess thhe OCD patients'symptom severity in the baseline, 2 weeks, 4weeks and after 8 weeks of the whole combined treatment. Through the study, Yale-Brown Obsessive Compulsive Scale(Y-BOCS), the Obsessive Compulsive Inventory-Revised (OCI-R), the Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI), Perceived Stress Scale (PSS), Pittsburgh sleep quality index (PSQI) and side-effect questionnaire will be obtained by a trained investigator. The patients will also get individual's data of EEG and eye-movement.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •age: 18-50 years old;
  • •Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for OCD;
  • •Y-BOCS total score > or = 16, discontinued medication for at least 8 weeks before
  • •the enrollment or the paitients' clinical medication is stable for at least a month (the dose and the types of drugs) .>or=9 years education

Exclusion Criteria

  • •Any axis I psychiatric disorder comorbidity
  • •Participants who have received any forms of psychological therapy in the past.
  • •Patients cannot tolerate or adapt to the somatic discomfort caused by VR .
  • •Prior history of neurological disease (e.g., epilepsy) or brain surgery for traumatic brain injury
  • •Participants with claustrophobic, heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body.
  • •Any current significant medical condition.
  • •serious suicide risk

Arms & Interventions

VR(ERP)

Active Comparator

The combination of exposure and response prevention (ERP) and VR will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total

Intervention: The combination of exposure and response prevention (ERP) and VR (Combination Product)

traditional ERP

Active Comparator

The traditional ERP will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total

Intervention: Traditional ERP (Behavioral)

Outcomes

Primary Outcomes

Change in Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score

Time Frame: from baseline to 8weeks

It assesses the severity of OCD symptoms. The Y-BOCS scale ranges from 0 to 40, with 0 being no symptoms and 40 being severe.The responder on Y-BOCS is defined as a Y-BOCS decrease at least 35% from the baseline at post-treatment.

Secondary Outcomes

  • Change in Beck Depression Inventory(BDI)(from baseline to 8weeks)
  • Change in Obsessive Compulsive Inventory-Revised(OCI-R)(from baseline to 8weeks)
  • Chinese version of Working Alliance Inventory-Short Form (WAI-SR)(assessed only once after the entire treatment at the end of the eighth week. (at the end week 8 ))
  • Change in Beck Anxiety Inventory (BAI)(from baseline to 8weeks)
  • Simulator Sickness Questionnaire(SSQ)(The SSQ should be assessed each time after the VR+ERP treating for OCD patients. (at week 2, 3, 4, 5, 6, 7))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Zhen Wang

vice-president

Shanghai Mental Health Center

Study Sites (1)

Loading locations...

Similar Trials